Back

A meta-analysis of high-dose versus low-dose 4-factor prothrombin complex concentrate for reversal of factor Xa inhibitor-associated intracerebral hemorrhage

25 August 2023 (15:15 - 15:50)
Organised by: Logo
Congress Presentation Part of: Psychiatric and neurologic disease: cardiovascular complications Neurologic Disorders and Heart Disease ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Craig Coleman

University of Connecticut, Storrs (United States of America)

6 More presentations in this session

Presentation thumbnail
Sudden cardiac death in people with schizophrenia: higher risk, poorer resuscitation profiles and differing pathologies
Doctor E. Paratz (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Evaluation of cardiovascular risk in the population with a diagnosis of organic mental illness, a cohort study carried out in South America
Doctor L. Dulcey (Merida, VE)
Abstract Slides Video
Presentation thumbnail
Severe mental illness and symptoms of acute coronary syndrome in emergency calls
Doctor A. Storgaard Noerskov (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Long-term risk of cardiovascular side-effects following attention-deficit hyperactivity disorder treatment with sympathomimetic amines
Mr A. Holt (Copenhagen, DK) Doctor S. Nielsen (Hellerup, DK)
Abstract Slides Video
Presentation thumbnail
Systematic review and meta-analysis of increased ischemic heart disease vulnerability in schizophrenia patients
Mr J. Wang (Trondheim, NO)
Abstract Slides Video

Access the full session

Session thumbnail
Psychiatric and neurologic disease: cardiovascular complications

The Event

Event poster

ESC Congress 2023

25 August 2023 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Effectiveness of high- versus low-dose four-factor prothrombin complex concentrate on hemostasis and thromboembolism in patients with oral factor Xa inhibitor-associated intracranial hemorrhage
thumbnail
Congress Presentation
Use of factor XI inhibitors compared with DOACs in atrial fibrillation and thromboembolism prevention: a systematic review and meta-analysis of randomized-controlled trials
thumbnail
Congress Presentation
Factor XI inhibitors in early clinical trials: a meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources